Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EXL03
- Development stage
- Preclinical
- Lead developer
- Exeliom Biosciences
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
01
Overview
EXL03 is a live biotherapeutic product developed by Exeliom Biosciences. It acts as a microbiome modulator and is intended for therapeutic use in various diseases, though specific indications are not detailed in the available information. It is currently in the preclinical phase.
Beyond the preview
Go deeper on EXL03.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EXL03.